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1. Introduction
Alveolar bone regeneration with grafting is often carried out prior to placement of dental
implants. Several graft materials have been used including autogenous bone, xenogeneic bone,
and synthetic bone substitutes. Autogenous bone grafts have been used for a long time with
good predictability and are considered the “gold standard” because of their osteoinductive
and osteoconductive properties and immunogenic compatibility. However, autogenous bone
must be harvested from a donor site of the patient and is associated with higher morbidity
(Arrington et al., 1996; Joshi et al., 2004). Xenogeneic bone and synthetic bone substitutes such
as deproteinized bovine bone, hydroxyapatite, and calcium triphosphate are often used
clinically as osteoconductive scaffolds, but they provide limited osteoinductivity and a
potential risk of infection and extrusion (Damien et al., 1991). Osteoinductive growth factors
such as bone morphogenic protein (BMP)-2 have been used with these osteoconductive
materials to promote bone regeneration (Herford & Boyne, 2008). However, recent studies
have indicated unexpected effects on bone regeneration including induction of a severe
inflammatory response, because of the higher dose with clinical application of BMP-2
(Kawasaki et al., 1998; Perri et al., 2007, Vaidya et al., 2007).
Recently, the concept of tissue engineering and regenerative medicine has been widely
accepted (Langer & Vacanti, 1993), and many clinical studies have been performed including
studies of bone and periodontal regenerative medicine.
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We previously developed a technique whereby autogenous human mesenchymal stem cells
(hMSCs) from the patient’s bone marrow are combined with platelet-rich plasma for use as an
alternative to such materials with predictable good prognosis (Yamada et al., 2004, 2013).
However, clinical use of stem cells requires highly qualified safety investigation and quality
management of cell handling, and is very expensive. These limitations currently impede the
widespread use of stem cells for alveolar bone regeneration therapy. Moreover, recent studies
have revealed that the implanted cells do not survive long (Ide et al., 2010; Perri et al., 2007;
Toma et al., 2009). As an alternative, the effects of the secretomes, the various factors secreted
into the medium, from stem cells on tissue repair and regeneration have attracted much
attention (Baglio et al., 2012; Chen et al., 2008; Ciapetti et al., 2012).
We have reported the effects of the secretomes in the conditioned medium from bone marrow-
derived mesenchymal stem cells (MSC-CM) on bone and periodontal tissue regeneration in
vitro and in vivo. MSC-CM contains several cytokines such as insulin-like growth factor (IGF)-1,
vascular endothelial growth factor (VEGF), and transforming growth factor (TGF)-β1. MSC-
CM enhances cell proliferation, mobilization, angiogenesis, and expression of osteogenic
markers such as alkaline phosphatase, collagen type I, and Runx2 genes (Katagiri et al., 2013). MSC-
CM also recruits endogenous stem cells to the grafted site and shows early bone and perio‐
dontal regeneration in rat calvarial bone defects and dog periodontal bone defects (Inukai et
al., 2013; Osugi et al., 2012). Furthermore, the concentrations of cytokines contained in MSC-
CM are relatively low such that use of MSC-CM does not induce the severe histological
inflammatory responses that are observed with the clinical use of recombinant human BMP-2
(Katagiri et al., 2013).
In this section, our in vitro and in vivo studies about the effects of MSC-CM on bone and
periodontal tissue regeneration were summarized and introduced.
2. Biological effects of MSC-CM in bore and periodontal tissue
regeneration
2.1. Preparation of MSC-CM
The hMSCs were purchased from Lonza and cultured in MSC basal medium (Lonza) with
MSC growth medium (SingleQuots, Lonza). Rat MSCs (rMSCs) were isolated from the femora
of 7-week-old Wistar/ST rats (Japan SLC) and expanded and cultured in Dulbecco’s modified
Eagle medium (DMEM) (Gibco) with 10% fetal bovine serum (FBS). Cells of the second to
fourth passages were used in the experiments in this study. Cells were maintained at 37°C in
5% carbon dioxide/95% air. The hMSCs were cultured in a culture dish (100 × 20 mm). When
hMSCs reached 70% to 80% confluence, the medium was refreshed with 10 mL of serum-free
DMEM containing antibiotics (100 units/mL penicillin G, 100 μg/mL streptomycin, and 0.25μg/
mL amphotericinB; Gibco). The culture media (CM) was collected after 48 hours of incubation.
This media was defined as hMSC culture-conditioned media (MSC-CM) and stored at 4°C or
–80°C before being used for subsequent experiments.












Table 1. The Levels of Cytokines Present in MSC-CM
2.2. Cytokines present in MSC-CM
The concentrations of the cytokines IGF-1, VEGF, TGF-β1, HGF, FGF-2, PDGF-BB, BMP-2, and
SDF-1α in MSC-CM were quantified with ELISA. Cytokines were not detected in DMEM-0%
and DMEM-30%. However, MSC-CM contained IGF-1, VEGF, TGF-β1, and HGF at concen‐
trations of 1386 ± 465, 468.5 ± 109, 339.8 ± 14.4, and 20.3 ± 7.8 pg/ml, respectively. The other
factors assayed were not detected in MSC-CM (Table 1).
2.3. MSC-CM enhances migration and proliferation of MSCs and PDLCs
The migratory properties of rMSCs and rPDLCs were examined using the CytoSelect Wound
Healing Assay kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s
instructions. Briefly, cell suspension was added to the well with a plastic insert in place. The
insert was removed from the well after a monolayer of cells had formed, creating a wound gap
of 0.9 mm. After washing, cells were incubated at 37 °C for 48 h in MSC-CM with 30% FBS or
serum-free DMEM. The extent of wound closure was determined with a light microscope
(CK40; Olympus, Tokyo, Japan) at ×40 magnification. The percentage of rMSCs in the wound
area of DMEM (−) was 9.28 ± 4.41. There were 70.9 ± 6.8% rMSCs in the wound area of positive
control (30% FBS). MSC-CM exerted significant effects (p < 0.05) and closed the wound to 43.4
± 10.6% rMSCs (Fig. 1a).
The percentage of rPDLCs in the wound area of DMEM (−) was 2.36 ± 2.32%, with 48.01 ± 6.28%
in 30% FBS and 17.98 ± 4.14% in MSC-CM. Thus, MSC-CM increased rMSC migration more
than four-fold and rPDLC migration more than seven-fold compared with that in DMEM (−).
These differences were statistically significant (p < 0.05), indicating that MSC-CM enhanced
rMSC and rPDLC migration and proliferation (Fig. 1b).
The level of cellular fill within the wound area in response to MSC-CM was compared with
the wound-fill response in the presence of 30% FBS or serum-free DMEM as control after 48 h
(a). The migration of rMSCs and rPDLSCs cultured in MSC-CM was enhanced compared with
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rMSCs and rPDLSCs cultured in DMEM (−). MSC-CM increased wound area more than 4-fold
compared to that in DMEM(-) (b, *p < 0.05).
2.4. MSC-CM enhanced MSC migration in rat calvarial bone defect model
rMSCs were harvested and cultured as described previously and were labeled with the
lipophilic tracer 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR; Molecu‐
lar Probes, Eugene, OR) for all imaging ex-periments (Kalchenko et al., 2006). This fluorophore
is excited at 750 nm and has an emission peak at 782 nm. The cells were incubated with DiR
(3 x106 cells in 10 mL PBS containing 3.5 mg/mL dye and 0.5% ethanol) for 30 min at 37°C. The
cells were then washed twice with PBS and injected intravenously into the caudal vein of
Wistar/ST rats with the bone defect de-scribed previously, which had been implanted with
vari-ous implant materials just before the injection of rMSCs. The rats were anesthetized by
intraperitoneal injection of Somnopentyl® prior to injection. Xenogen’s IVIS® 200 Series
Imaging System (Xenogen, Alameda, CA) was used to monitor DiR-labeled rMSC localization
within live, as well as sacrificed, animals. Imaging was performed at 1, 24, and 48h, and at 1
week after injection of DiR-labeled cells. Migration of rMSCs to the implants in vivo was
analyzed in rats of the different implantation groups in which DiR-labeled rMSCs were injected
into the caudal vein. Although it is not possible to detect DiR-labeled cells at a great depth
with the imaging system used, this system can detect DiR-labeled cells that accumulate on the
calvarial bone. The fluorescent signal in all groups increased immediately after injection. In
the control Defect group, the fluorescent signal of the labeled rMSCs was only detected in the
Figure 1. MSC-CM promoted migration and proliferation of rMSCs and rPDLCs in the wound-healing assay.
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tail and abdominal region at 1, 24, and 48 h, and at 1 week after injection. We confirmed that
there were no signals at the defect area in the cranium at any time point. In the PBS group,
fluorescent signals were observed in the tail and in the abdominal area at 24 and 48h after
injection, and very low signals were observed in the breast and cranial area after 1 week. In
the MSC-CM group, a moderate increase in signal intensity was observed in the area of the
tail and the abdominal region during the first 24h after injection. At 48h after injection, signal
intensity in the MSC-CM-implanted area of the parietal bone started to increase. The maximum
fluorescent signal in the implanted area was observed 1 week after injection (Fig. 2).
In vivo imaging analysis shows that DiR-labeled rMSCs that were injected into the caudal vein
just after implantation of the materials into the calvarial bone defects started to mi-grate
immediately after injection. At 24 h, 48 h, 72h and 1 week after injection, the signal of the
fluorescent-labeled rMSCs was only detected in the tail and abdominal region in the control
PBS group. In the MSC-CM group, a moderate increase in signal intensity was observed in the
abdominal region during the first 24 h after injection. Forty-eight hours after injection, the
MSC-CM-implanted area of calvarial bone started to increase in signal intensity, and, 1 week
after injection, the MSC-CM implanted area, as well as the implanted bone cavity, showed the
highest fluorescent signal of the experimental groups.
Figure 2. In vivo imaging of injected rMSC migration to implants.
2.5. MSC-CM enhanced osteogenic and angiogenic marker gene expression
The levels of expression of the ALP, OCN, Runx2, VEGF-A, ANG-1, and ANG-2 genes were
significantly upregulated in rMSCs cultured with MSC-CM compared with rMSCs cultured
in EM (Fig. 3).
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Figure 3. MSC-CM enhanced osteogenic and angiogenic marker gene expression.
The mRNA expression levels of ALP, OCN, Runx2, VEGF-A, ANG-1, and ANG-2 were deter‐
mined relative to the level of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA in each
sample and were quantified and standardized. The level of expression of the each gene was
significantly upregulated in rMSCs cultured with MSC-CM compared with rMSCs cultured
in DMEM (*p < 0.05).
2.6. MSC-CM enhanced bone regeneration, migration of endogeneous MSCs and
angiogenesis in rat calvarial bone defect model
Twenty-four 10-week-old male Wistar/ST rats were anesthetized by intraperitoneal injection
of pento-barbital (Somnopentyl, Kyoritsu Seiyaku) (20 mg/kg body weight). Two circular full-
thickness (through-and-through) bone defects (5 mm in diameter) were made in the calvarial
bone using a trephine bur and were irrigated with saline to remove the bone debris. The
experimental materials were then implanted into the defects. Atelocollagen (Terudermis,
Olympus Terumo Biomaterials), which was cut into the desired form, was suspended in MSC-
CM or PBS. Three groups were de-fined: (1) MSC-CM group: MSC-CM/Terudermis; (2) PBS
group: PBS/Terudermis; and (3) defect group: unfilled defect.
Rats were sacrificed at 2 or 4 weeks after transplantation (n=4 per group). The surgical sites
were dissected, fixed in 10% formalin, and subjected to micro-computed tomography (micro-
CT) analysis using a laboratory x-ray CT device (LATheta, Hitachi Aloka). Images were
compiled and analyzed to render three-dimensional images using OsiriX imaging software
(version 3.9). Then the area (mm2) of newly regenerated bone was compared between groups.
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The explants were decalci-fied with K-CX solution (FALMA) and dehydrated using a graded
series of ethanols, cleared with xylene, and embedded in paraffin. The specimens were cut in
a sagittal direction to make 3-μm-thick histologic sections and stained with hematoxylin-eosin.
Histologic analysis was performed using a light microscope. MSC-CM/Terudermis or control
implants were placed into rat calvarial bone defects (Fig 4a). The area of newly regenerated
bone was determined as a percentage of the total graft area at 2 and 4 weeks post-implantation
using micro-CT (Fig 4b). After 2 weeks, the mean area of newly regenerated bone in the MSC-
CM defects (81.50% ± 2.7%) was significantly increased compared to that of the unfilled defects
(8.63% ± 1.78%) and the PBS-treated sites (60.63% ± 5.8%). After 4 weeks, the defect areas were
almost completely filled by newly regenerated bone in the MSC-CM (93.07% ± 6.6%) and PBS
(84.04% ± 4.9%) groups (Fig 4b). Moreover, histologic analysis also showed well-regenerated
bone in the MSC-CM group compared with the PBS groups (Fig 5). At 2 weeks, the bone defect
was almost covered with newly regenerated bone in the MSC-CM group, in contrast to the
PBS group, where the defect was covered with a large amount of connective tissue. At 4 weeks,
newly regenerated bone was partially noticeable within the defect of the PBS group, but in the
MSC-CM group, the defect was almost completely replaced by mature bone tissue (Fig 5).
Figure 4. (a) Bone defect 5mm in diameter was prepared in each rat calvaria. (b) Micro-CT analysis of bone regenera‐
tion.
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Images of micro-CT indicated that the newly regenerated bone was seen at an early stage of
bone regeneration and almost covered the defect at 4 weeks. (c) Percent bone regeneration by
area within defects as measured by micro-CT at 2 and 4 weeks. MSC-CM increased the bone
regeneration significantly compared with other groups at 2 and 4 weeks (*p<0.01, #p<0.05).
Furethermore, we performed the immunohistochemical staining against CD31 and CD105
antibody to confirm the endogeneous MSC migration and angiogenesis during the bone
regeneration by MSC-CM. In the MSC-CM group, numerous CD31-or CD105--positive cells
were seen the MSC-CM implanted area. In contrast, there were fewer CD31-or CD105-positive
cells in both the PBS and Defect groups (Fig 6). These results indicated MSC-CM enhanced the
endogeneous MSC migration and angiogenesis.
Newly regenerated bone in the defect, PBS and MSC-CM groups 2 or 4 weeks after implanta‐
tion was evaluated. In the defect group, majority of the defect was filled with connectivetissue
and the infiltrations of inflammatory cells were seen both at 2 and 4 weeks. In the MSC-CM
group, newly regenerated bone had begun to cover the defect at 2 weeks and ossification had
progressed gradually. In the PBS group, newly regenerated bone and partial connective tissue
had covered the defect at 4 weeks.
Figure 5. Histological analysis of newly regenerated bone.
Two weeks after implantation into carvalial defects, tissue specimens were analyzed using
immunohistostaining for: CD31 (RED), a marker for rat endothelial cells; CD105 (GREEN), a
marker for rat stem cells. Cell nuclei were labeled with DAPI (blue). In MSC-CM group, both
CD105 and CD31 positive cells were more prominent than those of the control PBS group.
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2.7. MSC−CM enhanced periodontal tissue regeneration in dog periodontal defect model
All animal experiments were approved by the Nagoya University animal experiment com‐
mittee. After a period of acclimatization of 30 days, five hybrid dogs were operated on under
general anesthesia by intravenous injection of pentobarbital (Somnopentyl®) (20mg/kg body
weight), and under local anesthesia with 2% lidocaine (with 1:80,000 epinephrine, ORA® Inj.
Dental Cartridge; Showa Yakuhin Kako, Tokyo, Japan). Before the experimental surgery, the
mandibular first and third or fourth premolars were extracted, and the extraction sites were
allowed to heal for 8 weeks. For the experimental surgery, buccal and lingual mucoperiosteal
flaps were elevated, and critical-size, box-type, one-wall intrabony defects (width, 4mm;
height, 5 mm) were created at the distal aspect of the second, and the mesial aspect of the fourth
premolars in the right and left jaw quadrants (Kim, 2005). Following root planing to remove
the root cementum, a reference notch indicating a 5-mm distance from the cement-enamel
junction to the bottom of the defect was made with a burr into the root surface at the base of
the defects. With no differences in bone regeneration in the various grafted areas in terms of
bone healing, two defects were created and implanted with two materials at random sites. An
absorbable atelo-collagen sponge (TERUPLUG®; OLYMPUS TERUMO BIOMATERIALS,
Tokyo, Japan) was used as a scaffold and contained 300μl MSC-CM or PBS. The dogs with
defects were randomly divided into three groups (n=6 each) and implanted with graft
materials: MSC-CM plus scaffold, PBS plus scaffold, or unfilled defect. The mucogingival flaps
were advanced, adapted, and completely closed. Post-surgical management involved antibi‐
otics (Azithromycin, 250 mg; Pfizer, Tokyo, Japan) daily for 3 days, a soft diet, and topical
application of 2% chlorhexidine (Hibitane concentrate; Dainippon Sumitomo Pharma, Osaka,
Japan) twice a week. After 4 weeks, the dogs were given general anesthesia and sacrificed by
exsanguination after injection of heparin sodium (400 U/kg).
Standardized radiographic images of the defect sites were obtained with an X-ray apparatus
(Dent navi Hands; Yoshida Co., Ltd., Tokyo, Japan) and dental X-ray films (BW-100; Hanshin
Technical Laboratory, Nishinomiya, Japan) immediately, and 4 weeks after, transplantation.
Figure 6. Immunohistochemical analysis of newly generated bone area 2 weeks after implantation.
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Dental X-ray films were placed parallel to the tooth axis, and radiographic images of the defect
site were ta-ken in the buccolingual direction. The defect sites were dissected and fixed in 10%
neutral-buffered formalin (Wako, Japan) 4 weeks after transplantation. The specimens were
decalcified in Plank-Rychro solution (Wako) for 8 weeks, routinely processed into 5μm-thick
paraffin-embedded sections, stained with hematoxylin and eosin, and observed under a light
microscope (Olympus). Histometric parameters were quantified using a computer-based
image analysis system (Image J 1.44; National Institutes of Health). The following parameters
were analyzed:
1. Cementum regeneration height: distance from the root surface notch to the coronal
extension of newly formed cementum on the root surface.
2. Bone regeneration height: distance from the root surface notch to the coronal
extension of newly formed bone along the root surface.
3. Bone regeneration area: area of new alveolar bone formed coronally from the apical
extension of the root surface notch.
Clinical healing was generally uneventful. The results from the histometric analysis are shown
in Fig. 8. The cementum regeneration height, the bone regeneration height, and the bone
regeneration area of the MSC-CM group were 3.01 ± 0.16 mm, 3.19 ± 0.51 mm, and 4.89 ± 1.08
mm2, respectively. A large amount of new lamellar and woven bone formation was observed
in the MSC-CM group. Thick-layered and cellular cementum on the root surface was also
frequently observed in the MSC-CM group.
On the other hand, less newly regenerated bone and cementum compared to the MSC-CM
group was observed in the PBS group. Dense collagen fibers were observed frequently in the
PBS group. Newly regenerated bone and cementum were not apparent in the defect group.
Furthermore, there was minimal inflammatory cell infiltration in the MSC-CM group com‐
pared to the other groups.
Figure 7. Representative photomicrographs and radiographic images from sites receiving experimental materials.
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White arrows: osteoblasts. Black arrows: newly regenerated cellular cementum. Photomicrographs: hematoxylin and
eosin staining.
Figure 8. (A, E and I) overview of periodontal defect site. Original magnification x12.5, scale bar=1 mm. (B, C, F, G, J
and K) Higher magnification of the boxed areas. Original magnification x100, scale bar=50 lm. (D, H and L) Radio‐
graphic images were taken at 0 (left) and 4 weeks (right) after surgery. Histometric analysis of periodontal regenera‐
tion following surgical implantation of MSC-CM/TERUPLUG® in dog one-wall intrabony defects (means ± SD in mm or
mm2) (p < 0.05).
3. Conclusion
From the results of these studies, it was suggested that MSC-CM contributes to upregulation
of several processes of bone and periodontal tissue regeneration through the angiogenesis and
mobilization of endogenous MSCs, and thus enhanced bone and periodontal tissue regener‐
ation. Using MSC-CM for bone and periodontal tissue regeneration may be effective because
several cytokines, including MSC-CM, contribute several processes to the complex system of
bone and periodontal tissue regeneration. If the MSC-CM treatment protocol is to be estab‐
lished for bone and periodontal tissue regeneration, it is essential that effective and therapeutic
doses of MSC-CM as well as the safety of the therapy should be carefully established. Further
investigation regarding these matters is now in progress.
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